Innate Pharma announces new data from TELLOMAK study

Innate Pharma (IPHA) announced new data highlighting the quality-of-life improvements observed in patients with cutaneous T-cell lymphoma, or CTCL, treated with lacutamab in the TELLOMAK Phase 2 clinical study. These data were presented at the 66th American Society of Hematology, or ASH, annual meeting in San Diego, California. The TELLOMAK study addresses an unmet need for patients with advanced-stage CTCL, particularly Sezary syndrome and mycosis fungoides, who often experience debilitating symptoms such as severe itching and recurrent skin infections that profoundly impact their physical and social well-being. Patients with relapsed or refractory CTCL face limited treatment options and often report lower health-related quality of life, particularly those in advanced stages. TELLOMAK’s findings reveal signs that lacutamab may help alleviate some of the most distressing symptoms of this disease early on treatment. The TELLOMAK trial enrolled 163 patients with advanced CTCL, including 56 with SS and 107 with MF. The study’s quality of life measures included the Visual Analogue Scale, or VAS, for itch intensity and the Skindex-29 score, a validated tool for assessing the impact of skin conditions on patient quality of life.